

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Next List](#)[Bottom](#)[View Cart](#)

Searching 1976 to present...

Results of Search in 1976 to present db for:

SPEC/("pharmaceutically acceptable additives": 793 patents.

Hits 1 through 50 out of 793

Next 50 Hits

Jump To

Refine Search spec/("pharmaceutically acceptable additives")

PAT.
NO.

Title

- 1 [6,506,407](#) **T** [Colon-specific drug release system](#)
- 2 [6,500,839](#) **T** [CRF receptor antagonists and methods relating thereto](#)
- 3 [6,498,246](#) **T** [Glycosaminoglycan derivatives and processes for preparing same](#)
- 4 [6,498,244](#) **T** [Adeno-associated virus capsid immunologic determinants](#)
- 5 [6,498,139](#) **T** [Remedies for diseases caused by insulin resistance](#)
- 6 [6,495,547](#) **T** [\(Benzodioxan, benzofuran or benzopyran\) derivatives having fundic relaxation properties](#)
- 7 [6,495,537](#) **T** [Method for inhibition of photocarcinogenesis or photoimmunosuppression using niacin](#)
- 8 [6,492,408](#) **T** [Small molecules useful in the treatment of inflammatory disease](#)
- 9 [6,492,330](#) **T** [Antiangiogenic drugs](#)
- 10 [6,491,904](#) **T** [Topical composition containing human epidermal growth factor](#)
- 11 [6,489,514](#) **T** [\(-\)-Secoisolariciresinol as an antioxidant obtained from a new natural source namely stereospermum personatum](#)
- 12 [6,485,745](#) **T** [Solid oral dosage forms of valsartan](#)
- 13 [6,482,836](#) **T** [CRF antagonistic quino- and quinazolines](#)
- 14 [6,482,823](#) **T** [Taste masked pharmaceutical liquid formulations](#)
- 15 [6,482,802](#) **T** [Use of neomycin for treating angiogenesis-related diseases](#)
- 16 [6,479,074](#) **T** [Methods and transdermal compositions for pain relief](#)
- 17 [6,476,017](#) **T** [Compounds activating pharmacological effect of retinoids](#)
- 18 [6,475,508](#) **T** [Methods and pharmaceutical compositions for the closure of retinal breaks](#)
- 19 [6,475,490](#) **T** [Compositions and methods for promoting tissue repair using heat shock proteins](#)

- 20 6,472,528 **T** Synthesis of substituted pyrazolopyrimidines
- 21 6,472,388 **T** Aralkyl and aralkylidene heterocyclic lactams and imides
- 22 6,469,166 **T** Thiophenopyrimidines
- 23 6,469,062 **T** Use of 15-keto-prostaglandins in promoting bile secretion
- 24 6,469,025 **T** 3-substituted isoquinolin-1-yl derivatives
- 25 6,469,023 **T** Heterocyclic spiro-derivative
- 26 6,465,502 **T** Additional therapeutic use
- 27 6,465,500 **T** Indole derivatives as 5-HT1 agonists
- 28 6,465,471 **T** Cinnamic acid derivatives
- 29 6,465,004 **T** Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
- 30 6,462,048 **T** Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant) agonists of 5-HT1A- and/or 5-HT1D receptors
- 31 6,462,047 **T** Carboline derivatives as cGMP phosphodiesterase inhibitors
- 32 6,462,040 **T** Cis-substituted aminocyclopropane derivative
- 33 6,461,615 **T** Therapeutic and prophylactic methods using heat shock proteins
- 34 6,458,960 **T** Sulfonamide derivatives
- 35 6,458,840 **T** Use of valproic acid analog for the treatment and prevention of migraine and affective illness
- 36 6,458,782 **T** Remedies for diabetes
- 37 6,458,373 **T** Emulsion vehicle for poorly soluble drugs
- 38 6,455,539 **T** Squaric acid derivatives
- 39 6,455,048 **T** Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes
- 40 6,452,013 **T** Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
- 41 6,451,803 **T** N-acyl and n-aroyl aralkyl amides useful in treating seritonerger disorders
- 42 6,451,802 **T** S-oxide lipid lowering compounds
- 43 6,451,307 **T** 3'-exonuclease, production and use thereof
- 44 6,448,266 **T** Substituted cyclobutylamine derivatives
- 45 6,447,781 **T** Therapeutic and prophylactic methods using heat shock proteins
- 46 6,447,780 **T** Prevention of primary and metastatic neoplastic diseases with hsp90-peptide complexes
- 47 6,444,849 **T** Amide derivatives
- 48 6,444,679 **T** 4-phenyl-4-heteroaryl piperidine derivatives
- 49 6,444,477 **T** Assay method for detecting 5-HT2B antagonists
- 50 H2,044 **T** Container with retaining member

[Next List](#)[Top](#)[View Cart](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)